Please enable Javascript
Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Translational Study Suggests Rationale for Targeting CXCL8/CXCR2 Pathway in Myelofibrosis
Cecilia Brown
Myelofibrosis
|
March 21, 2023
Hematopoietic stem/progenitor cells from patients with myelofibrosis are “enriched” for a CXCL8/CXCR2 gene signature.
Read More
Pelabresib Plus Ruxolitinib ‘Well-Tolerated’ in Myelofibrosis
Cecilia Brown
Myelofibrosis
|
March 16, 2023
A reduction in spleen volume reduction of ≥35% at 24 weeks occurred in 68% of patients.
Read More
Momelotinib Leads to ‘Clinically Significant Improvements’ Over Danazol in Myelofibrosis
Cecilia Brown
Myelofibrosis
|
February 8, 2023
The study’s investigators are continuing to monitor overall survival and conduct ongoing patient follow-up.
Read More
Primary Myelofibrosis Mortality Risk Halved After Ruxolitinib Approval
Cecilia Brown
Myelofibrosis
|
January 24, 2023
The overall risk of death from primary myelofibrosis declined by more than 50% after the U.S. FDA approved ruxolitinib.
Read More
CALR Mutation in Myelofibrosis Associated with Greater Risk of Anemia
Kerri Fitzgerald
Meeting News
|
December 19, 2022
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Read More
John Mascarenhas, MD, on the Phase III PACIFICA Trial of Pacritinib in Myelofibrosis
Leah Sherwood
Meeting News
|
December 13, 2022
John Mascarenhas, MD, discusses the results of the PACIFICA trial at the 2022 American Society of Hematology Annual Meeting.
View More
Advertisement
Parsaclisib Added to Ruxolitinib for Myelofibrosis Improves Symptoms and Spleen Volume
Keightley Amen
Meeting News
|
December 12, 2022
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Read More
TP53 and Complex Karyotype Are High-Risk Factors in HSCT for Myelofibrosis
Keightley Amen
Myelofibrosis
|
December 10, 2022
TP53 and complex karyotype are very high-risk factors in patients with myelofibrosis undergoing HSCT.
Read More
Phase I/II Trial Reports Safety, Efficacy of Ruxolitinib, IFNα2a in Patients with Myelofibrosis
Keightley Amen
Myelofibrosis
|
December 10, 2022
The combination of ruxolitinib and pegylated IFNα2a showed significant reductions in spleen length.
Read More
Researchers Present Early Data on BET Inhibitor BMS-986158 in Myelofibrosis
Keightley Amen
Meeting News
|
December 10, 2022
BMS-986158 combined with ruxolitinib or fedratinib reduced spleen volume in patients with myelofibrosis.
Read More
Phase I Study Demonstrates Benefit of Combination Selinexor, Ruxolitinib for Treatment-Naïve Myelofibrosis
Kerri Fitzgerald
Myeloproliferative Neoplasms
|
December 10, 2022
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Read More
Transfusion-Independence, Survival Improved in Patients with Myelofibrosis Receiving Momelotinib
Kerri Fitzgerald
Myeloproliferative Neoplasms
|
December 10, 2022
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Read More
Luspatercept has ‘Limited Therapeutic Value’ in Anemia, Myelofibrosis
Cecilia Brown
Myelodysplastic Syndromes
|
December 7, 2022
Findings from a new study “underscore the limited therapeutic value of luspatercept” in anemia and myelofibrosis.
Read More
Which Conditioning in High-Risk Myelofibrosis Has Better Outcomes?
Leah Sherwood
Myeloproliferative Neoplasms
|
November 29, 2022
Those with MF with high molecular and cytogenetic risk do not benefit from higher intensity conditioning before transplant.
Read More
Adding Navitoclax to Ruxolitinib Reduces Spleen Volume in Myelofibrosis
Cecilia Brown
Myeloproliferative Neoplasms
|
November 16, 2022
Adding navitoclax to ruxolitinib led to durable spleen volume reductions and improved total symptoms in myelofibrosis.
Read More
Study IDs Risk Factors for Thrombosis, Major Bleeding in Myelofibrosis
Cecilia Brown
Myeloproliferative Neoplasms
|
November 16, 2022
There are several risk factors for thrombosis and major bleeding in patients with myelofibrosis, according to a recent study.
Read More
Real-World Data Show Myelofibrosis Outcomes 'Remain Poor’ with Ruxolitinib
Leah Sherwood
Myeloproliferative Neoplasms
|
October 28, 2022
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Read More
MOMENTUM Compares Momelotinib, Danazol in Thrombocytopenic Myelofibrosis
Leah Sherwood
Myeloproliferative Neoplasms
|
October 28, 2022
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
Read More
Acquired In Utero Mutation Found in Twins with Myelofibrosis
Kerri Fitzgerald
Myeloproliferative Neoplasms
|
October 20, 2022
A recent case study found evidence of an acquired in utero mutation in monozygotic twins who presented with CALR.
Read More
Predicting Ruxolitinib Treatment Outcomes in Myelofibrosis
Kerri Fitzgerald
Myeloproliferative Neoplasms
|
October 20, 2022
A new prognostic model identified risk factors for reduced survival in patients with myelofibrosis who received ruxolitinib.
Read More
Load More
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MD
Associate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University